The DOI matches its Crossref record; 50 of the 50 references it cites were found in a registry or an index.
Association of Low Plasma Aβ42/Aβ40 Ratios With Increased Imminent Risk for Mild Cognitive Impairment and Alzheimer Disease
Abstract
BACKGROUND: To develop preventive therapy for Alzheimer disease (AD), it is essential to develop AD-related biomarkers that identify at-risk individuals in the same way that cholesterol levels identify persons at risk for heart disease. OBJECTIVE: To determine whether plasma levels of amyloid beta protein (Abeta40 and Abeta42) are useful for identifying cognitively normal elderly white subjects at increased risk for mild cognitive impairment (MCI) and AD. DESIGN: Using well-established sandwich enzyme-linked immunosorbent assays, plasma Abeta40 and Abeta42 levels were analyzed at baseline in a prospective, elderly white cohort followed up for 2 to 12 (median, 3.7) years to detect incident cases of MCI or AD. SETTING: Cognitively normal, community-based white volunteers recruited from primary care settings into the Mayo Rochester Alzheimer Disease Patient Registry. Patients We followed up 563 cognitively normal white volunteers (median age, 78 years; 62% female) who had at least 1 follow-up visit after measurement of baseline plasma Abeta levels. MAIN OUTCOME MEASURES: The primary outcome was time to development of MCI or AD. The secondary outcome was the annualized rate of cognitive change in patients for whom we had 2 Mattis Dementia Rating Scale evaluations 3 to 7 years apart. RESULTS: During follow-up, 53 subjects developed MCI or AD. Subjects with plasma Abeta42/Abeta40 ratios in the lower quartiles showed significantly greater risk of MCI or AD (P = .04, adjusted for age and apolipoprotein E genotype). Comparison of subjects with plasma Abeta42/Abeta40 ratios in the lowest vs the highest quartile gave a relative risk of 3.1 (95% confidence interval, 1.1-8.3). After adjusting for age and apolipoprotein E genotype, regression analysis using annualized changes in the Dementia Rating Scale scores as an outcome variable showed that participants with lower Abeta42/Abeta40 ratios had greater cognitive decline (P = .02). CONCLUSION: The plasma Abeta42/Abeta40 ratio may be a useful premorbid biomarker for identifying cognitively normal elderly white subjects who are at increased risk for developing MCI or AD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
McKhann, G., Drachman, D., Folstein, M., Katzman, R., Price, D., & Stadlan, E. M. (1984) · Neurology · doi:10.1212/wnl.34.7.939 · Cited by 27,915
Staging of brain pathology related to sporadic Parkinson’s disease
Braak, H., Tredici, K. D., Rüb, U., de Vos, R. A. I., Jansen Steur, E. N. H., & Braak, E. (2003) · Neurobiology of Aging · doi:10.1016/s0197-4580(02)00065-9 · Cited by 10,777
The Clinical Dementia Rating (CDR): Current version and scoring rules
Morris, J. C. (1993) · Neurology · doi:10.1212/wnl.43.11.2412-a · Cited by 9,882
Mild Cognitive Impairment: Clinical Characterization and Outcome
Petersen, R. C., Smith, G. E., Waring, S. C., Ivnik, R. J., Tangalos, E. G., & Kokmen, E. (1999) · Archives of Neurology · doi:10.1001/archneur.56.3.303 · Cited by 8,980
Self-citationMild cognitive impairment as a diagnostic entity
Petersen, R. C. (2004) · Journal of Internal Medicine · doi:10.1111/j.1365-2796.2004.01388.x · Cited by 7,864
Self-citationThe Neuropsychiatric Inventory: Comprehensive assessment of psychopathology in dementia
Cummings, J. L., Mega, M., Gray, K., Rosenberg-Thompson, S., Carusi, D. A., & Gornbein, J. (1994) · Neurology · doi:10.1212/wnl.44.12.2308 · Cited by 7,568
Dauer, W., & Przedborski, S. (2003) · Neuron · doi:10.1016/s0896-6273(03)00568-3 · Cited by 5,469
Current concepts in mild cognitive impairment
Petersen, R. C., Doody, R., Kurz, A., Mohs, R. C., Morris, J. C., Rabins, P. V., Ritchie, K., Rossor, M., Thal, L., & Winblad, B. (2001) · Archives of Neurology · doi:10.1001/archneur.58.12.1985 · Cited by 4,781
Self-citationL'examen psychologique ; Dans les cas d'ence-phalopathie traumatique (Les problemes)
Rey, A. (1941) · Medical Entomology and Zoology · Cited by 3,262
Psychological Assessment Resources
Abidin, R. R. (1995) · Medical Entomology and Zoology · Cited by 3,147
Unified Parkinson's Disease Rating Scale
(2012) · SpringerReference · doi:10.1007/springerreference_184495 · Cited by 3,066
Scheuner, D., Eckman, C., Jensen, M., Song, X., Citron, M., Suzuki, N., Bird, T. D., Hardy, J., Hutton, M., Kukull, W., et al. (1996) · Nature Medicine · doi:10.1038/nm0896-864 · Cited by 2,599
Self-citation(2025) · Springer Reference Medizin · doi:10.1007/978-3-662-65186-5_302294 · Cited by 2,278
Reynolds, C. R., & Powel, J. (1988) · Archives of Clinical Neuropsychology · doi:10.1093/arclin/3.4.397 · Cited by 2,095
Caughey, B., & Lansbury, P. T. (2003) · Annual Review of Neuroscience · doi:10.1146/annurev.neuro.26.010302.081142 · Cited by 1,650
McKhann, G., Drachman, D., Folstein, M., Katzman, R., Price, D., & Stadlan, E. M. (2011) · Neurology · doi:10.1212/01.wnl.0000400650.92875.cf · Cited by 1,495
MULTI-INFARCT DEMENTIA A CAUSE OF MENTAL DETERIORATION IN THE ELDERLY
HACHINSKI, V (1974) · The Lancet · doi:10.1016/s0140-6736(74)91496-2 · Cited by 1,093
Kawarabayashi, T., Younkin, L. H., Saido, T. C., Shoji, M., Ashe, K. H., & Younkin, S. G. (2001) · The Journal of Neuroscience · doi:10.1523/jneurosci.21-02-00372.2001 · Cited by 1,053
Self-citationROTHMAN, K. J., GREENLAND, S., & WALKER, A. M. (1980) · American Journal of Epidemiology · doi:10.1093/oxfordjournals.aje.a113015 · Cited by 859
The pedunculopontine nucleus and Parkinson's disease
Pahapill, P. A. (2000) · Brain · doi:10.1093/brain/123.9.1767 · Cited by 831
Where Does Parkinson Disease Pathology Begin in the Brain?
Del Tredici, K., Rüb, U., de Vos, R. A. I., Bohl, J. R. E., & Braak, H. (2002) · Journal of Neuropathology & Experimental Neurology · doi:10.1093/jnen/61.5.413 · Cited by 773
Pathology of Parkinson’s disease: Changes other than the nigrostriatal pathway
Jellinger, K. A. (1991) · Molecular and Chemical Neuropathology · doi:10.1007/bf03159935 · Cited by 684
Yamada, M., Mitsuno, S., Kato, S., & Hirano, H. (1997) · PubMed · Cited by 683
Amyloid β Protein (Aβ) in Alzheimeri's Disease Brain
Gravina, S. A., Ho, L., Eckman, C. B., Long, K. E., Otvos, L., Younkin, L. H., Suzuki, N., & Younkin, S. G. (1995) · Journal of Biological Chemistry · doi:10.1074/jbc.270.13.7013 · Cited by 676
Self-citationConsensus Report of the Working Group on: “Molecular and Biochemical Markers of Alzheimer’s Disease”
(1998) · Neurobiology of Aging · doi:10.1016/s0197-4580(98)00022-0 · Cited by 666
Evaluation of CSF-tau and CSF-Aβ42 as diagnostic markers for Alzheimer disease in clinical practice
Andreasen, N., Minthon, L., Davidsson, P., Vanmechelen, E., Vanderstichele, H., Winblad, B., & Blennow, K. (2001) · Archives of Neurology · doi:10.1001/archneur.58.3.373 · Cited by 573
Plasma Aβ1–40 and Aβ1–42 and the risk of dementia: a prospective case-cohort study
van Oijen, M., Hofman, A., Soares, H. D., Koudstaal, P. J., & Breteler, M. M. (2006) · The Lancet Neurology · doi:10.1016/s1474-4422(06)70501-4 · Cited by 458
Parkinson's--Divergent Causes, Convergent Mechanisms
Greenamyre, J. T., & Hastings, T. G. (2004) · Science · doi:10.1126/science.1098966 · Cited by 451
Plasma Aβ40 and Aβ42 and Alzheimer’s disease: Relation to age, mortality, and risk
Mayeux, R., Honig, L. S., Tang, M.-X., Manly, J., Stern, Y., Schupf, N., & Mehta, P. D. (2003) · Neurology · doi:10.1212/01.wnl.0000091890.32140.8f · Cited by 434
The Short Test of Mental Status: Correlations With Standardized Psychometric Testing
Kokmen, E. (1991) · Archives of Neurology · doi:10.1001/archneur.1991.00530190071018 · Cited by 333
α‐Synuclein pathology does not predict extrapyramidal symptoms or dementia
Parkkinen, L., Kauppinen, T., Pirttilä, T., Autere, J. M., & Alafuzoff, I. (2005) · Annals of Neurology · doi:10.1002/ana.20321 · Cited by 315
Hobson, P., & Meara, J. (2004) · Movement Disorders · doi:10.1002/mds.20216 · Cited by 312
Unified Parkinson’s Disease Rating Scale
Fish, J. (2011) · Encyclopedia of Clinical Neuropsychology · doi:10.1007/978-0-387-79948-3_1836 · Cited by 297
Striatal dopamine deficiency in parkinson's disease: Role of aging
Scherman, D., Desnos, C., Darchen, F., Pollak, P., Javoy‐Agid, F., & Agid, Y. (1989) · Annals of Neurology · doi:10.1002/ana.410260409 · Cited by 286
The Rate of Cognitive Decline in Parkinson Disease
Aarsland, D., Andersen, K., Larsen, J. P., Perry, R., Wentzel-Larsen, T., Lolk, A., & Kragh-Sørensen, P. (2004) · Archives of Neurology · doi:10.1001/archneur.61.12.1906 · Cited by 283
Age but Not Diagnosis Is the Main Predictor of Plasma Amyloid β-Protein Levels
Fukumoto, H., Tennis, M., Locascio, J. J., Hyman, B. T., Growdon, J. H., & Irizarry, M. C. (2003) · Archives of Neurology · doi:10.1001/archneur.60.7.958 · Cited by 257
Combined effect of age and severity on the risk of dementia in Parkinson's disease
Levy, G., Schupf, N., Tang, M., Cote, L. J., Louis, E. D., Mejia, H., Stern, Y., & Marder, K. (2002) · Annals of Neurology · doi:10.1002/ana.10219 · Cited by 209
Jellinger, K. A. (2003) · Acta Neuropathologica · doi:10.1007/s00401-003-0725-y · Cited by 201
Biochemistry of Parkinson's disease 28 years later: A critical review
Agid, Y., Cervera, P., Hirsch, E., Javoy-Agid, F., Lehericy, S., Raisman, R., & Ruberg, M. (1989) · Movement Disorders · doi:10.1002/mds.870040514 · Cited by 163
Elevated plasma amyloid β-peptide 1–42 and onset of dementia in adults with Down syndrome
Schupf, N., Patel, B. N., Silverman, W. P., Zigman, W. B., Zhong, N., Tycko, B., Mehta, P. D., & Mayeux, R. P. (2001) · Neuroscience Letters · doi:10.1016/s0304-3940(01)01657-3 · Cited by 161
Clinical observations on the rate of progression of idiopathic parkinsonism
Lee, C. S., Schulzer, M., Mak, E., Snow, B. J., Tsui, J. K. C., Clane, S., Hammerstad, J. P., & Clane, D. B. (1994) · Brain · doi:10.1093/brain/117.3.501 · Cited by 147
Regional Distribution of α-Synuclein Pathology in Unimpaired Aging and Alzheimer Disease
Parkkinen, L., Soininen, H. S., & Alafuzoff, I. I. (2003) · Journal of Neuropathology & Experimental Neurology · doi:10.1093/jnen/62.4.363 · Cited by 139
Differential progression of motor impairment in levodopa-treated Parkinson's disease
Goetz, C. G., Stebbins, G. T., & Blasucci, L. M. (2000) · Movement Disorders · Cited by 91
Which factors predict cognitive decline in Parkinson's disease?
Caparros-Lefebvre, D., Pécheux, N., Petit, V., Duhamel, A., & Petit, H. (1995) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp.58.1.51 · Cited by 70
The record of independent living
Weıntraub, S. (1986) · American Journal of Alzheimer s Disease & Other Dementias® · doi:10.1177/153331758600100210 · Cited by 69
Heritability of plasma amyloid β in typical late‐onset Alzheimer’s disease pedigrees
Ertekin‐Taner, N., Graff‐Radford, N. R., Younkin, L. H., Eckman, C. B., Adamson, J. L., Schaid, D. J., Blangero, J., Hutton, M. L., & Younkin, S. G. (2001) · Genetic Epidemiology · doi:10.1002/gepi.1015 · Cited by 60
Self-citationBlasko, I., Kemmler, G., Krampla, W. W., Jungwirth, S., Wichart, I., Jellinger, K. A., Tragl, K. H., & Fischer, P. A. (2005) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2005.03.006 · Cited by 46
Editorial Board, Burns, A. S., Challis, D., Dennis, J., Hughes, J., Burns, A. S., Byrne, E. J., Findlay, D., & Dementia, V. (2013) · Routledge eBooks · doi:10.4324/9780203120804-11 · Cited by 26
Blasko, I., Kemmler, J., Krampla, W. W., Jungwirt, S., Wichard, I., Jellinger, K. A., Tragl, K. H., & Fischer, P. A. (2005) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2005.06.081 · Cited by 15
Kordower (1999) · doi:10.1002/1531-8249(199909)46:3
Cited by
Preclinical Alzheimer’s Disease: Definition, Natural History, and Diagnostic Criteria
Dubois, B., Hampel, H., Feldman, H. H., Scheltens, P., Aisen, P., Andrieu, S., Bakardjian, H., Benali, H., Bertram, L., Blennow, K., et al. (2016) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2016.02.002 · Cited by 1,925
Cerebrospinal fluid and plasma biomarkers in Alzheimer disease
Blennow, K., Hampel, H., Weiner, M., & Zetterberg, H. (2010) · Nature Reviews Neurology · doi:10.1038/nrneurol.2010.4 · Cited by 1,863
Fiandaca, M. S., Kapogiannis, D., Mapstone, M., Boxer, A., Eitan, E., Schwartz, J. B., Abner, E. L., Petersen, R. C., Federoff, H. J., Miller, B. L., et al. (2015) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2014.06.008 · Cited by 959
Self-citationXiao, Y., Ma, B., McElheny, D., Parthasarathy, S., Long, F., Hoshi, M., Nussinov, R., & Ishii, Y. (2015) · Nature Structural & Molecular Biology · doi:10.1038/nsmb.2991 · Cited by 818
Post-Stroke Cognitive Impairment and Dementia
Rost, N. S., Brodtmann, A., Pase, M. P., van Veluw, S. J., Biffi, A., Duering, M., Hinman, J. D., & Dichgans, M. (2022) · Circulation Research · doi:10.1161/circresaha.122.319951 · Cited by 790
Metadata
- Authors
- Graff-Radford, N. R., Crook, J. E., Lucas, J., Boeve, B. F., Knopman, D. S., Ivnik, R. J., Smith, G. E., Younkin, L. H., Petersen, R. C., & Younkin, S. G.
- Venue
- Archives of Neurology
- Publisher
- American Medical Association (AMA)
- Published
- 2007-03-01
- Volume
- 64
- Issue
- 3
- Pages
- 354
- ISSN
- 0003-9942 (ISSN-L)
- OpenAlex
- W1966613471
- Cited by
- 441
- References
- 50
- FWCI
- 22.38
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.